Clinical response correlates with 4-week postinjection ustekinumab concentrations in patients with moderate-to-severe psoriasis.

ABSTRACT:

Background

Cost-effective use of biologicals is important. As drug concentrations have been linked to clinical outcomes, monitoring drug concentrations is a valuable tool to guide clinical decision-making. A concentration-response relationship for ustekinumab at trough is uncertain owing to the contradictory results reported.

Objectives

To investigate the relationship between 4-week postinjection ustekinumab concentrations and clinical response in patients with psoriasis.

Methods

Forty-nine patients with moderate-to-severe psoriasis treated with 45 mg or 90 mg ustekinumab every 12 weeks for ≥ 16 weeks were included. Ustekinumab serum concentrations and anti-ustekinumab antibodies were measured at week 4 after injection and disease severity was assessed by Psoriasis Ar

SUBMITTER: Van den Berghe N 

PROVIDER: S-EPMC7028119 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature